Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH)

2022412 citationsJournal Article

Authors

The addition of TACE to LEN improves clinical outcomes and is a potential first-line treatment for patients with advanced HCC.

Good health and well-being

Published in: Journal of Clinical Oncology

Volume 41, Issue 1, pp. 117-127

Field-Weighted Citation Impact: 53.78